The historical rank and industry rank for Burning Rock Biotech's OCF Margin % or its related term are showing as below:
FRA:6BU0'
s OCF Margin % Range Over the Past 10 Years
Min: -120.27 Med: -59.75 Max: -5.27
Current: -6.84
During the past 9 years, the highest OCF Margin % of Burning Rock Biotech was -5.27%. The lowest was -120.27%. And the median was -59.75%.
FRA:6BU0's OCF Margin % is ranked worse than 64.04% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.67
vs FRA:6BU0: -6.84
Burning Rock Biotech OCF Margin % Related Terms
Burning Rock Biotech OCF Margin % Historical Data
* Premium members only.
The historical data trend for Burning Rock Biotech's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6BU0 vs XGN, IDXG, PRPO: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Burning Rock Biotech's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Burning Rock Biotech (FRA:6BU0) has a OCF Margin % of -27.15% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Burning Rock Biotech and its competitors. According to the industry distribution chart, Burning Rock Biotech ranks #130 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 64%.
Is Burning Rock Biotech's OCF Margin % too high?
Burning Rock Biotech's current OCF Margin % is -27.15%. Based on the distribution chart, Burning Rock Biotech ranks #130 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Burning Rock Biotech has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's OCF Margin % compare to XGN and IDXG?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #130 out of 203 companies for OCF Margin %. This places Burning Rock Biotech in the lower half of its industry. The industry median OCF Margin % is 4.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.67, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Burning Rock Biotech and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Burning Rock Biotech's current OCF Margin % is -27.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (FRA:6BU0) is currently considered Fairly Valued. The stock's GF Value™ is €5.43, compared to a current price of €6.00 — trading 10.5% above its estimated fair value. The current OCF Margin % is -27.15%. Burning Rock Biotech's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Burning Rock Biotech (FRA:6BU0), the current OCF Margin % is -27.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of €6.00 is trading 10.5% above its estimated GF Value™ of €5.43.
GuruFocus considers Burning Rock Biotech to be Fairly Valued.
Key valuation signals for FRA:6BU0:
OCF Margin %: -27.15%
GF Value™: €5.43 vs. price of €6.00 (10.5% above fair value)
No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
59GF Score
Get the complete analysis for FRA:6BU0
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6BU0 has been successfully added to your 
